Steve Harr

Steve Harr (chief executive) discloses dealings in 2 companies, chiefly Juno Therapeutics, Inc. and Sana Biotechnology, Inc. The record holds 39 filings, for trades running from 10 December 2015 to 9 March 2026.

On the market, this insider has only sold: 15 sales, €4.7M in total. Outside the open market, there are 8 share grants and 6 option exercises.

The latest filing, published on 10 March 2026, reports a share grant of €34k in Sana Biotechnology, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.